

NYSSA CORPORATION LIMITED

CIN: L70101MH1981PLC024341

Office No - 002, Gulmohar Complex, Opposite Anupam Cinema, Station Road, Goregaon (E), Mumbai-400 063.

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER /PERIOD ENDED 31st DECEMBER., 2018

(₹. in Lakhs)

Table with 12 columns: Particulars, Standalone (31.12.2018 Unaudited, 30.09.2018 Unaudited, 31.12.2017 Unaudited, 31.12.2018 Unaudited, 31.12.2017 Unaudited, 31.03.2018 Audited), Consolidated (31.12.2018 Unaudited, 30.09.2018 Unaudited, 31.12.2017 Unaudited, 31.12.2018 Unaudited, 31.12.2017 Unaudited, 31.03.2018 Audited). Rows include Total Income, Profit/(loss) before exceptional and extraordinary items, Profit/(loss) after tax, Total comprehensive income, and Earnings per share.

The above is an extract of the detailed format of Quarterly/Half year Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Half year Financial Results are available on the websites of the Bombay Stock Exchange(s) and the company. (www.bseindia.com and www.nyssa.com)

BY BOARD OF DIRECTOR FOR NYSSA CORPORATION LTD DIRECTOR PRASANNA YADAV SHIRKE DIN: 07654053

Place: Mumbai Date: 14/02/2019



DUCON INFRA TECHNOLOGIES LIMITED

Regd. Office: Ducon House, Plot No. A/4, Road No. 1, MIDC, Wagale Industrial Estate, Thane 400604 CIN No: L72900MH2009PLC191412 Web site: www.duconinfra.co.in Contact no.022-41122115

Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2018

(₹ in lakhs)

Table with 6 columns: Particulars, Quarter ended (December 31, 2018, September 30, 2018, December 31, 2017), Nine Months ended (December 31, 2018, December 31, 2017), Year ended (31.03.2018). Rows include Total Income from Operations, Net Profit after taxes and minority interest, Net Profit after tax & minority interest, Equity Share Capital, Reserves, Earnings Per Share, and Basic/Diluted EPS.

Note: a) The above is an extract of the detailed format of Quarterly and Nine Months Financial Results filed with the Stock Exchanges on 14th February, 2019 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine Months Financial Results are available on the Company's website www.duconinfra.co.in and on the Stock Exchange website www.bseindia.com and www.nseindia.com. b) The Financial results of the Company for the quarter /nine months ended 31st December 2018, have been prepared in accordance with the Indian Accounting Standard (IndAS) as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules 2015, as amended.

Thane 14-Feb-19

For Ducon Infratechnologies Ltd. and on behalf of the Board of Directors Sd/- Harish Shetty Director Din No: 07144684



Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2018

(₹ in Millions)

Large financial statement table with 19 columns: Particulars, Standalone (Ind AS) (Quarter ended 31-12-2018, 30-09-2018, 31-12-2017, Nine Months ended 31-12-2018, 31-12-2017, Year ended 31-03-2018), Consolidated (Ind AS) (Quarter ended 31-12-2018, 30-09-2018, 31-12-2017, Nine Months ended 31-12-2018, 31-12-2017, Year ended 31-03-2018), Consolidated (IFRS) (Quarter ended 31-12-2018, 30-09-2018, 31-12-2017, Nine Months ended 31-12-2018, 31-12-2017, Year ended 31-03-2018). Rows include Revenue from operations, Expenses, Profit/(loss) before exceptional items, Profit/(loss) before tax, Tax expense, Profit/(loss) for the period from continuing operations, Total comprehensive income, and Earnings per share.

Notes: 1. The Financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015. 2. The above results were reviewed by the Audit Committee at its meeting held on 13 February, 2019 and approved at the meeting of the Board of Directors held on 14 February, 2019. 3. The results for the quarter and nine months ended 31 December, 2018 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results. 4. On 1 January 2019, the Company completed the transfer of the Company's API business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company. 5. During the quarter, the Company bought back U.S.\$86,500,000 in aggregate principal amount of the Foreign Currency Convertible Bonds (FCCB). As of 31 December, 2018, U.S.\$113,500,000 in aggregate principal amount of FCCB are outstanding, resulting in gain on extinguishment of liability of Rs. 153.72 million. 6. "Exceptional item: Exceptional items in the standalone (Ind AS) financial results for the nine months ended 31 December, 2018, primarily comprises of net gain of Rs. 3,451.85 million towards the sale of Orthopaedic and Pain management India business (Ortho India business). Exceptional items in the consolidated financial results (Ind AS and IFRS) for the nine months ended 31 December 2018 primarily comprises of the gain of Rs. 3,451.85 million towards the sale of Ortho India business and effect of de-prioritization of certain intangibles aggregating to Rs. 1,780.03 million." 7. Post implementation of Goods and Service Tax (GST) with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for nine months ended 31 December, 2018 is not comparable with previous periods presented. 8. Effective 1 April, 2018, the Company adopted IND AS 115 or IFRS 15 "Revenue from Contracts with customers", as the case may be using the modified retrospective transition method. There was no material effect on the financial results on adoption of IND AS 115 or IFRS 15, as the case may be. 9. The list of subsidiaries as of 31 December, 2018 is provided in Annexure A. 10. The Company operates in one reportable business segment i.e., Pharmaceuticals. 11. As at 31 December, 2018, pursuant to Employee Stock Options Scheme 2016, 4,59,414 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. 12. Diluted EPS has been computed considering the effect of conversion of ESOPs. 13. Previous period's figures have been re-grouped/re-classified wherever necessary.

Annexure A List of entities included in the consolidated financial results for the quarter and nine months ended 31 December 2018 Name of Entities: 1)Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2)Glenmark Pharmaceuticals Europe Ltd., U.K. 3)Glenmark Pharmaceuticals S.R.O. 4)Glenmark Pharmaceuticals SK, S.R.O. 5) Glenmark Pharmaceuticals S. A. 6)Glenmark Holding S.A. 7)Glenmark Pharmaceuticals S.R.L 8)Glenmark Pharmaceuticals SP z.o.o. 9) Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Generics Inc.) 10)Glenmark Therapeutics Inc. 11) Glenmark Farmaceutica Ltda 12)Glenmark Generics S.A 13) Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14)Glenmark Pharmaceuticals Peru SAC 15)Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) 16)Glenmark Uruguay S.A. 17)Glenmark Pharmaceuticals Venezuela, C.A 18)Glenmark Dominicana SRL 19)Glenmark Pharmaceuticals Egypt S.A.E. 20)Glenmark Pharmaceuticals FZE 21)Glenmark Impex L.L.C 22)Glenmark Philippines Inc. 23)Glenmark Pharmaceuticals (Nigeria) Ltd 24)Glenmark Pharmaceuticals Malaysia Sdn Bhd 25)Glenmark Pharmaceuticals (Australia) Pty Ltd 26)Glenmark South Africa (pty) Ltd 27)Glenmark Pharmaceuticals South Africa (pty) Ltd 28)Glenmark Pharmaceuticals (Thailand) Co. Ltd 29)Glenmark Pharmaceuticals B.V.(Formerly known as Glenmark Generics B.V.) 30) Glenmark Arzneimittel GmbH 31) Glenmark Pharmaceuticals Canada Inc. (formerly known as Glenmark Generics Canada Inc.) 32) Glenmark Pharmaceuticals Kenya Ltd 33)Glenmark Therapeutics AG 34)Viso Farmaceutica S.L., Spain 35)Glenmark Specialty SA 36)Glenmark Pharmaceuticals Distribution s.r.o. 37)Glenmark Pharmaceuticals Nordic AB 38)Glenmark Ukraine LLC 39)Glenmark-Pharmaceuticals Ecuador S.A. 40)Glenmark Pharmaceuticals Singapore Pte. Ltd. 41)Glenmark Biotherapeutics SA 42)Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited)

For and on behalf of the Board of Directors Glenn Saldanha Chairman & Managing Director

Mumbai, February 14, 2019

